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estimated. Model variables included insurer’s type, age, gender,
charlson comorbidity index, year. Odd ratios(OR) and 95%
conﬁdence intervals(CI) were used to investigate the impact of
medicaid expansion on PH trend. The PHwas deﬁned as a class of
admission believed to be preventable in most cases by standard
ambulatory health care before admission. The marker admissions
were determined such as appendicitis and gastrointestinal
obstruction, remaining relatively constant across populations.
RESULTS: Among newly enrolled 140,366 medicaid population,
62.1% were female, mean age was 52 years old. These percentage
of female and mean age among 280,301 NHI population were
53.1% and 39 years old, respectively. The biennial ratio of PH
relative to marker admission in medicaid population increased
after eligibility expansion, from an average of 6.05 to
9.04(OR = 1.50). This rise was small compared with the NHI
populations, who experienced from 1.96 to 3.22(OR = 1.64).
After adjusting for confounding variables, the OR for after med-
icaid expansion among medicaid population and NHI population
were 1.48(95% CI = 1.29–1.69) and 1.71(95% CI = 1.53–1.91),
respectively. CONCLUSIONS: Current ﬁndings suggest that the
medicaid PH trend was less likely to rise than NHI PH trend after
implementing medicaid expansion.
PODIUM SESSION IV: OUTCOMES RESEARCH ISSUES
OR1
EXAMINING ASSOCIATION BETWEEN PATIENT-REPORTED
OUTCOMES AND CLINICAL OUTCOMES USING PROBIT
REGRESSION ANALYSIS
Conlon J1, Xu X2, Zlateva G3, Knight T2
1Covance, Inc, Princeton, NJ, USA, 2Covance Market Access Services
Inc, Gaithersburg, MD, USA, 3Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: The purpose of this study is to examine the
impact of visual acuity (VA) on bilateral neovascular age-related
macular degeneration (nvAMD) patients’ general quality of life
(QOL). Instead of the traditional correlation/linear regression
analysis, a novel approach using PROBIT regression on cumula-
tive QOL rates was employed. METHODS: Data from a
cross-sectional, multi-country (France, Germany, Spain, UK and
Canada) burden of nvAMD was examined (n = 401 nvAMD
patients). As part of the telephone interview, patients completed
EQ-5D as the assessment of general quality of life (QOL). Asso-
ciations between VA and EQ-5D were examined using traditional
Pearson correlation, analysis of variance (ANOVA) test of
EQ-5D score as a function of VA level (normal, mild, moderate,
severe, and near blindness), and PROBIT regression. In the
PROBIT regression, the decimal VA was ordinalized into catego-
ries centered at 0.02, 0.04, 0.06, etc., and cumulative QOL rates
were calculated at each of these levels. RESULTS: Pearson cor-
relation and one-way analysis of variance tests showed no sig-
niﬁcant association between VA and EQ-5D. From the PROBIT
regression, the inﬂection points were determined and the mean
and standard deviation of the underlying normal distribution
were estimated. The inﬂection points identify the VA levels at
which association between QOL and VA may be expected and at
what level no association would occur. The mean and SD dem-
onstrate where the relationship was linear. While the Pearson
correlation showed a 0.01 correlation coefﬁcient between EQ-5D
and VA, PROBIT regression showed a 0.89 correlation coefﬁ-
cient, with the association being linear between VA range of 0.02
and 0.40. CONCLUSIONS: The association of VA levels and
EQ-5D is affected by many extraneous variables that make it
difﬁcult to identify the strength of the association. The use of
PROBIT regression gives researchers an important methodologi-
cal tool to strengthen their understanding of such associations.
OR2
INCORPORATING DIFFUSION OF NEW MEDICINES IN A
BUDGET IMPACT ANALYSIS
ter Borg J1,Al MJ2
1IMS Health, Den Haag,The Netherlands, 2Erasmus MC, Rotterdam,
The Netherlands
OBJECTIVES: When a budget impact analysis is performed for
the introduction of a new drug, the diffusion of the drug needs to
be forecasted. Such forecast should be as evidence-based as pos-
sible if it is to be useful for health care decision makers. We
assessed the usefulness of several models for predicting the diffu-
sion of new drugs on the Dutch market. METHODS: Several
diffusion models were assessed, and the most useful in the context
of a new drug entering the market was selected. Next, historical
diffusion was analysed based on Farminform and IMS data. This
data provides sales (volume) at the level of the active substance for
the total Dutch market each month. Data was available from
January 1993 until October 2006. We included data on 22
products divided over 6 ATC 2 categories (ATC = Anatomical
Therapeutic Chemical). RESULTS: We found that the Hahn
model is most applicable for new drugs. The Hahn model was
capable of describing diffusion retrospectively of the 22 drugs
studied. The results provide insight in the diffusion pattern which
can be used to forecast diffusion of new interventions. Based on
these empirically derived descriptors of diffusion some ﬁndings
were: The biggest growth (relative to the previous period) of a
product is achieved between roughly 12 and 36 months; No
products are observed with a market (ATC2) penetration of more
than 45%; In less than a ﬁfth of the introductions, a market share
ofmore than 20%at theATC2 level is achievedwithin 60months;
In less than a tenth of the introductions, a market share of more
than 35% at the ATC 2 level is achieved within 60 months.
CONCLUSIONS: The assumptions about market diffusions cur-
rently made in budget impact analyses can be greatly improved if
formal models are used to predict diffusion.
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ADJUSTING ICERS FOR FUTURE UNRELATED MEDICAL
COSTS: DEVELOPMENT AND APPLICATION OF ATOOLKIT
De Wit GA,Tariq L,Wong A, Polder JJ, van Baal P
National Institute of Public Health and the Environment, Bilthoven,
The Netherlands
OBJECTIVES: Most international pharmacoeconomic guide-
lines advise not to include future unrelated medical costs in
economic evaluations. Recently, arguments in favor of inclusion
of such costs are gaining support in health economic literature.
However, correct estimations of these costs do not yet exist. This
paper describes the methodology with which we developed a
toolkit to adjust incremental cost-effectiveness ratios (ICER) for
future unrelated medical costs, and presents an application of the
toolkit by adjusting the ICER of universal hepatitis B vaccination
of newborns. METHODS: We deﬁned three variables that
predict individual health care expenditure best: age, sex and time
to death. However, the relation between health care expenditure
and these three variables depends on the lethality of diseases and
on health care setting. For the development of the toolkit, differ-
ent cross-sectional and longitudinal databases were used. First,
the 2003 Dutch Cost of Illness study has been employed. Fur-
thermore, insurance claims data and longitudinal record linkage
data were used. This allowed us to estimate how the relation
between time to death and health care costs is altered if costs of
related diseases are excluded. To apply the toolkit, survivor
curves for the intervention and control groups are needed. For
hepatitis B vaccination of newborns, future unrelated medical
costs (i.e. all costs not related to hepatitis B infection and
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sequelae) are added using the differences between survivor curves
of Hepatitis B infected persons and population survivor curves.
RESULTS: Without the inclusion of future unrelated medical
costs, Hepatitis B vaccination costs €900 per life year gained.
Adjusting the ICER for these costs results in an increase to
approximately €5.700 per life year gained. CONCLUSIONS: We
conclude that the adjusted ICER provides more evidence-based
and transparant information about the real cost-effectiveness of
an intervention.
OR4
UTILITIES SHOULD NOT BE MULTIPLIED: EVIDENCE FROM
THE PREFERENCE-BASED SCORES INTHE UNITED STATES
Fu AZ, Kattan MW
Cleveland Clinic, Cleveland, OH, USA
OBJECTIVES: Several estimators exist when average utility
scores are not available for patient populations with multiple
disease conditions. The multiplicative estimator is a widespread
choice among them. Our study is to empirically test the accuracy
of the multiplicative estimator and compare it with other estima-
tors. METHODS: The Medical Expenditure Panel Survey
(MEPS) has a nationally representative sample of the US civilian
non-institutionalized population. Using the pooled 2001 and
2003 data, a sample of 40,846 individuals with EQ-5D index
scores were categorized into 238 disease condition categories.
The study focus was the difference between the estimated and the
observed mean scores for each comorbid pair, with the observed
one presumed to be the true value. RESULTS: The scores esti-
mated by multiplying the two mean scores of the corresponding
disease conditions on average had a statistically signiﬁcantly
larger difference (p < 0.0001) from the observed ones (-0.094)
than simply picking the smaller mean of the two paired condi-
tions (difference = 0.025), the larger mean of the two (differ-
ence = 0.071), the average of the two means (difference = 0.048),
or the mean of the condition with smaller sample size of the pair
(difference = 0.049). However, the multiplicative estimator per-
formed better than the additive estimator (sum of the means
minus 1, difference = 0.123). CONCLUSIONS: Multiplication is
not a good estimate when the average utility score for patients
with two disease conditions is not readily available. The lower of
the two utility scores had the least error among those estimators
that we compared. Further research with an experimental
design is warranted before a speciﬁc alternative can be ﬁrmly
recommended.
POSTER SESSION I
HEALTH CARE USE & POLICY STUDIES—
Consumer Role in Health Care
PHP1
PATIENTS’ PREFERENCES FOR AND PRICE ELASTICITY OF
GENERIC AND BRANDED OVER-THE-COUNTER
MEDICINES—AN ADAPTIVE CONJOINT ANALYSIS
(ACA) APPROACH
Halme ML1, Linden K2
1Helsinki School of Economics, Helsinki, Finland, 2Pﬁzer Oy, Helsinki,
Finland
OBJECTIVES: Despite the increased use of generic medicines,
little is known about patients’ attitudes towards them and
patients’ decision-making process of the medicine purchased.
The aim of the study is to assess the patients’ preference struc-
ture for generic and branded over-the-counter (OTC) pain medi-
cines and their price elasticity. METHODS: Finnish university
students (n = 209) responded to an adaptive conjoint analysis
(ACA) interview. Product attributes of price, brand, onset time
of effect, place of purchase and source of information were
included on the basis of the literature, a focus group and a pilot
study. The descriptors of the respondents included socioeco-
nomic background, involvement with the purchase process, and
health behavior. Individual-level utility functions were esti-
mated, preference clusters identiﬁed, and price elasticity of the
generic medicine estimated. RESULTS: Brand and price were
the most important attributes. Even in the homogenous target
group, ﬁve clusters with characteristic preferences, price elastic-
ity and socioeconomics background were detected. Approxi-
mately half of the respondents were strongly price sensitive.
Among all the respondents, the price elasticity of a generic OTC
medicine was from -1.34 to -0.69 at the discount range of
20–60%. Even positive price elasticity was detected. In the clus-
ters with negative price elasticity, discount of 4–42% were
required to make the generic medicine equally preferred with
the branded one. In comparison with the results of our corre-
sponding study conducted before the launch of generic substi-
tution leading to common interest in generic medicines and
medicine costs in Finland, patients’ awareness of generic medi-
cines had increased, attitudes towards them were more favor-
able, and they seemed to purchase OTC medicines more
independently. CONCLUSIONS: The study provided novel
information on the concomitant effects of brand, price and
other essential product attributes on the patients’ choice of an
OTC medicine. ACA proved to be a useful tool in the research
of patients’ and patient groups’ preferences.
PHP2
CONSUMERS’ PERCEPTIONS OF DRUG EFFECTIVENESS
AND PRICES IN GREECE
Tsiantou V1, Roubou I2, Pavi E1, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2NOVARTIS
(HELLAS) S.A.C.I, Athens, Greece
OBJECTIVES: Investigate Greek adults’ perceptions of drug
effectiveness and prices. METHODS: A structured questionnaire
was used in a telephone survey in order to derive data from a
national random sample of 1000 adults, stratiﬁed by age, gender
and geographic region. Physicians and pharmacists were
excluded from the sample. The study was conducted in June
2007. The response rate was 93.0%. RESULTS: Drugs were
considered by the majority of respondents (75.7%) as safe and
effective as well as very important for medical practice (65.2%).
Respondents believed that new drugs are of a higher price
(67.8%), however these were perceived as more effective than
older ones (79.4%) Regarding the prices of drugs in Greece, one
out of two respondents believed that the prices are extremely
high. Women as opposed to men expressed the less positive
opinion on the implemented pricing policy. The majority of
respondents (81.4%) recognized that the cost of R&D should be
included into the price of the drugs, but they think that the
pricing regulation of drugs is in favor of pharmaceutical indus-
tries (90.1%). Furthermore, they expressed the opinion that
prices should be as low as possible regardless of the effectiveness.
On the other hand, they claimed that physicians should always
prescribe the most effective drug regardless of its price. The
majority of respondents (89.4%) reported that polypharmacy
and irrational prescribing are major problems in Greece and
considered doctors to be primarily responsible, followed by the
absence of audit in the health system. CONCLUSIONS: Despite
the fact that drugs prices are considered high, Greek adults have
a strong positive view regarding their safety and effectiveness.
Knowledge on both the public’s perception regarding drugs and
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